A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

ABSTRACT:

Introduction

In Parkinson's disease (PD), anxiety is common, associated with lower health-related quality of life, and undertreated. The primary objective of this study was to determine the tolerability of buspirone for the treatment of anxiety in PD.

Methods

Individuals with PD and clinically significant anxiety were randomized 4:1 to flexible dosage buspirone or placebo for 12 weeks. Treatment was initiated at 7.5 mg twice daily and titrated based on response and tolerability to an optimal dosage (maximum 30 mg twice daily). The primary outcome was the proportion of participants who failed to complete the study on study drug. Secondary outcomes included adverse events, dosage reductions, motor function, dyskinesias, and anxiety.

Results

A total of 21 participants en

SUBMITTER: Schneider RB 

PROVIDER: S-EPMC7770052 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature